Yll Hoxha

Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019

Retrieved on: 
Friday, January 14, 2022
CAGR, EMA, European Medicines Agency, Rutgers University, NYSE, NASDAQ, Assistant, Robert Wood Johnson Medical School, Fulvestrant, Saudi Research and Marketing Group, ADC, TSX, PD-1, Oncolytics Biotech, Rutgers Cancer Institute of New Jersey, Safety, AstraZeneca, Pfizer, Roche Diagnostics, Clinical trial, Death, TME, TNBC, Letter, FDA, Daiichi Sankyo, Patient, State, Hoffmann-La Roche, IRENE, Program, News, DXD, Neoplasm, Trial of the century, ONC, Disability-adjusted life year, Breast cancer, CEO, Yll Hoxha, PFE, OTC, MD, Dietary supplement, Pharmaceutical industry, Medical imaging, Research, BC, Medicine, Cancer

Among the data, researchers witnessed that global cancer rates were up by +26% and that breast cancer was the leading cause of cancer-related disability-adjusted life years (DALYs), deaths, and years of life lost (YLLs) among females globally in 2019.

Key Points: 
  • Among the data, researchers witnessed that global cancer rates were up by +26% and that breast cancer was the leading cause of cancer-related disability-adjusted life years (DALYs), deaths, and years of life lost (YLLs) among females globally in 2019.
  • According to Research and Markets, the global breast cancer drugs market is expected to grow to $19.49 billion by 2025 at a CAGR of 7.1%.
  • Within its Breast Cancer Program so far, Oncolytics has witnessed a more-than-doubling of overall survival in metastatic HR+/HER2- breast cancer patients treated with pelareorep in IND-213as seen from study results delivered in 2017.
  • The IRENE study remains ongoing and will continue to enroll patients at the Rutgers Cancer Institute ofNew Jerseyand theOhio State UniversityComprehensive Cancer Center.

Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019

Retrieved on: 
Friday, January 14, 2022
CAGR, EMA, European Medicines Agency, Rutgers University, NYSE, NASDAQ, Assistant, Robert Wood Johnson Medical School, Fulvestrant, Saudi Research and Marketing Group, ADC, TSX, PD-1, Oncolytics Biotech, Rutgers Cancer Institute of New Jersey, Safety, AstraZeneca, Pfizer, Roche Diagnostics, Clinical trial, Death, TME, TNBC, Letter, FDA, Daiichi Sankyo, Patient, State, Hoffmann-La Roche, IRENE, Program, News, DXD, Neoplasm, Trial of the century, ONC, Disability-adjusted life year, Breast cancer, CEO, Yll Hoxha, PFE, OTC, MD, Dietary supplement, Pharmaceutical industry, Medical imaging, Research, BC, Medicine, Cancer

VANCOUVER, BC, Jan. 14, 2022 /PRNewswire/ -- USA News Group - Cancer cases are on the rise, according to a new study comparing the number of cancer diagnoses globally in 2010 and 2019. Among the data, researchers witnessed that global cancer rates were up by +26% and that breast cancer was the leading cause of cancer-related disability-adjusted life years (DALYs), deaths, and years of life lost (YLLs) among females globally in 2019. According to Research and Markets, the global breast cancer drugs market is expected to grow to $19.49 billion by 2025 at a CAGR of 7.1%. Among the biotech developers working into 2022 on new treatments for breast cancer are Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Roche Holding AG (OTC:RHHBY), Pfizer Inc. (NYSE:PFE), Incyte Corporation (NASDAQ:INCY) and AstraZeneca PLC (NASDAQ:AZN).

Key Points: 
  • Among the data, researchers witnessed that global cancer rates were up by +26% and that breast cancer was the leading cause of cancer-related disability-adjusted life years (DALYs), deaths, and years of life lost (YLLs) among females globally in 2019.
  • According to Research and Markets, the global breast cancer drugs market is expected to grow to $19.49 billion by 2025 at a CAGR of 7.1%.
  • Within its Breast Cancer Program so far, Oncolytics has witnessed a more-than-doubling of overall survival in metastatic HR+/HER2- breast cancer patients treated with pelareorep in IND-213as seen from study results delivered in 2017.
  • The IRENE study remains ongoing and will continue to enroll patients at the Rutgers Cancer Institute ofNew Jerseyand theOhio State UniversityComprehensive Cancer Center.